Lisata Therapeutics (NASDAQ:LSTA – Get Rating) and Progyny (NASDAQ:PGNY – Get Rating) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, valuation, profitability and analyst recommendations.

Valuation & Earnings

This table compares Lisata Therapeutics and Progyny's revenue, earnings per share (EPS) and valuation.

Progyny has higher revenue and earnings than Lisata Therapeutics. Lisata Therapeutics is trading at a lower price-to-earnings ratio than Progyny, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

Profitability

This table compares Lisata Therapeutics and Progyny's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent recommendations for Lisata Therapeutics and Progyny, as provided by MarketBeat.com.

Lisata Therapeutics currently has a consensus target price of $15.00, suggesting a potential upside of 500.00%. Progyny has a consensus target price of $54.33, suggesting a potential upside of 76.41%. Given Lisata Therapeutics' higher possible upside, equities analysts plainly believe Lisata Therapeutics is more favorable than Progyny.

Risk & Volatility

Lisata Therapeutics has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500. Comparatively, Progyny has a beta of 1.55, meaning that its stock price is 55% more volatile than the S&P 500.

Summary

Progyny beats Lisata Therapeutics on 11 of the 12 factors compared between the two stocks.

About Lisata Therapeutics

(Get Rating)

Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

About Progyny

(Get Rating)

Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.

Receive News & Ratings for Lisata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lisata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.